+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Universal HIV screening of pregnant women in England: Cost effectiveness analysis



Universal HIV screening of pregnant women in England: Cost effectiveness analysis



BMJ 318(7199): 1656-1660



Objective To estimate the cost effectiveness of universal, voluntary HIV screening of pregnant women in England. Design Cost effectiveness analysis. Cost estimates of caring for HIV positive children were based on the stage of HIV infection and calculated using data obtained from a London hospital between 1986 and 1996. These were combined with estimates of the health benefits and costs of antenatal screening so that the cost effectiveness of universal, voluntary antenatal screening for HIV infection in England could be estimated. Main outcome measures Lifetime, direct costs of medical care of childhood HIV infection; life years gained as a result of the screening programme; net cost per life year gained for different pretest counselling costs; and different prevalence rates of pregnant women who were unaware that they were HIV positive. Results Estimated direct lifetime medical and social care costs of childhood HIV infection were pnd178 300 using a 5% discount rate for time preference (1995-6 prices). In high prevalence areas screening pregnant women for HIV is estimated to be a cost effective intervention with a net cost of less than pnd4000 for each life year gained. For areas with comparatively low prevalence rates, cost effectiveness could be less than pnd20 000 per life year gained, depending on the number of pregnant women who are unaware that they are infected and local screening costs. Conclusions Our results confirm recent recommendations that universal, voluntary antenatal HIV screening should be implemented in the London area. Serious consideration of the policy should be given for other areas in England depending on local prevalence and screening costs.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 011613610

Download citation: RISBibTeXText

PMID: 10373167

DOI: 10.1136/bmj.318.7199.1656


Related references

Cost-effectiveness analysis of universal screening for thyroid disease in pregnant women in Spain. Endocrinologia Y Nutricion 62(7): 322-330, 2017

Cost-Effectiveness of Universal Hepatitis C Virus Screening of Pregnant Women in The United States. Clinical Infectious Diseases 2019, 2019

Cost-effectiveness of universal and risk-based screening for autoimmune thyroid disease in pregnant women. Journal of Clinical Endocrinology and Metabolism 97(5): 1536-1546, 2012

Cost-effectiveness of universal compared with voluntary screening for human immunodeficiency virus among pregnant women in Chicago. Pediatrics 105(4): E54, 2000

Screening for HBsAg in pregnant women: a cost analysis of the universal screening policy in the province of Quebec. Canadian Journal of Public Health 82(3): 191-195, 1991

Cost-Effectiveness Analysis of Screening Syphilis Among Pregnant Women. Value in Health 17(7): A509-A510, 2014

The cost-effectiveness of universal late-pregnancy screening for macrosomia in nulliparous women: a decision-analysis. Bjog 2019, 2019

Cost-effectiveness analysis of Chlamydia trachomatis screening in Dutch pregnant women. Pathogens and Global Health 110(7-8): 292-302, 2017

Screening pregnant women for autoimmune thyroid disease: a cost-effectiveness analysis. European Journal of Endocrinology 158(6): 841-851, 2008

Cost-effectiveness analysis of HIV screening in pregnant women in hospitals in the Paris region. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction 19(1): 36-42, 1990

Cost and cost-effectiveness of transitioning to universal initiation of lifelong antiretroviral therapy for all HIV-positive pregnant and breastfeeding women in Swaziland. Tropical Medicine and International Health 23(9): 950-959, 2018

Should all pregnant diabetic women undergo a fetal echocardiography? A cost-effectiveness analysis comparing four screening strategies. Prenatal Diagnosis 26(1): 39-44, 2005

Universal Quad screen versus universal cell free Dna testing for Downs syndrome screening: cost-effectiveness analysis. American Journal of Obstetrics and Gynecology 214(1): S381-S382, 2016

Cost-effectiveness of universal isoniazid preventive therapy among HIV-infected pregnant women in South Africa. International Journal of Tuberculosis and Lung Disease 22(12): 1435-1442, 2019

Cost-effectiveness of first trimester non-invasive fetal RHD screening for targeted antenatal anti-D prophylaxis in RhD-negative pregnant women: a model-based analysis. Bjog 123(8): 1337-1346, 2018